Technical Analysis for MYOV - Myovant Sciences Ltd.

Grade Last Price % Change Price Change
grade F 12.43 -3.19% -0.41
MYOV closed down 3.19 percent on Friday, May 24, 2019, on 85 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical MYOV trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -3.19%
Oversold Stochastic Weakness -3.19%
Calm After Storm Range Contraction -3.42%
Narrow Range Bar Range Contraction -3.42%
NR7 Range Contraction -3.42%
Wide Bands Range Expansion -3.42%

Older signals for MYOV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Chemistry Biopharmaceutical Pain Prostate Cancer Endocrine System Hormones Amines Pyrimidines Gnrh Antagonists Gonadotropin Releasing Hormone Antagonist Roivant Sciences Uterine Fibroids
Is MYOV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.45
52 Week Low 11.6499
Average Volume 151,218
200-Day Moving Average 20.3441
50-Day Moving Average 19.447
20-Day Moving Average 15.5255
10-Day Moving Average 13.229
Average True Range 1.054
ADX 54.57
+DI 7.9352
-DI 41.7551
Chandelier Exit (Long, 3 ATRs ) 15.538
Chandelier Exit (Short, 3 ATRs ) 14.8119
Upper Bollinger Band 20.5381
Lower Bollinger Band 10.5129
Percent B (%b) 0.19
BandWidth 64.572478
MACD Line -2.0013
MACD Signal Line -1.8347
MACD Histogram -0.1666
Fundamentals Value
Market Cap 756.29 Million
Num Shares 60.8 Million
EPS -1.63
Price-to-Earnings (P/E) Ratio -7.63
Price-to-Sales 0.00
Price-to-Book 5.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.51
Resistance 3 (R3) 13.57 13.28 13.33
Resistance 2 (R2) 13.28 13.00 13.25 13.27
Resistance 1 (R1) 12.85 12.83 12.71 12.79 13.21
Pivot Point 12.56 12.56 12.48 12.53 12.56
Support 1 (S1) 12.13 12.28 11.99 12.07 11.65
Support 2 (S2) 11.84 12.11 11.81 11.59
Support 3 (S3) 11.41 11.84 11.53
Support 4 (S4) 11.35